Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for ...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...

Mice that were fed diets high in fat and sugar developed immune system abnormalities in their livers, including reduced numbers of natural killer T (NKT) cells. These diet-related changes may ...

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.

Results show that percutaneous hepatic perfusion with CHEMOSAT® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in ...

Recently, a study revealed that CD36 expression and palmitoylation are regulated by the tumor suppressor gene EVA1A in hepatocellular carcinoma, making it a key regulator of hepatic lipid metabolism.

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.